$2.54 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 106 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | HORIZON PHARMA PLC | $226,302,000 | -0.6% | 13,740,261 | 0.0% | 8.89% | -8.3% | |
| AVXS | AVEXIS INC | $85,039,000 | +39.6% | 2,236,701 | 0.0% | 3.34% | +28.8% | |
| XNPT | XENOPORT INC | $81,468,000 | +56.1% | 11,572,125 | 0.0% | 3.20% | +44.1% | |
| HORIZON PHARMA INVT LTDnote 2.500% 3/1 | $75,166,000 | +6.7% | 82,600,000 | 0.0% | 2.95% | -1.6% | ||
| HEALTHWAYS INCnote 1.500% 7/0 | $72,000,000 | +2.0% | 76,925,000 | 0.0% | 2.83% | -5.9% | ||
| VNDA | VANDA PHARMACEUTICALS INC | $67,103,000 | +33.9% | 5,996,691 | 0.0% | 2.64% | +23.6% | |
| FLML | FLAMEL TECHNOLOGIES SAsponsored adr | $43,742,000 | -2.7% | 4,072,809 | 0.0% | 1.72% | -10.2% | |
| EDIT | EDITAS MEDICINE INC | $41,709,000 | -29.4% | 1,709,400 | 0.0% | 1.64% | -34.8% | |
| ARRAY BIOPHARMA INCnote 3.000% 6/0 | $37,815,000 | +5.4% | 45,000,000 | 0.0% | 1.49% | -2.7% | ||
| ENDOLOGIX INCnote 2.250%12/1 | $37,787,000 | +26.5% | 40,941,000 | 0.0% | 1.48% | +16.7% | ||
| WRIGHT MED GROUP INCnote 2.000% 2/1 | $36,749,000 | +2.2% | 40,050,000 | 0.0% | 1.44% | -5.7% | ||
| ACOR | ACORDA THERAPEUTICS INC | $26,255,000 | -3.6% | 1,029,410 | 0.0% | 1.03% | -11.0% | |
| AXGN | AXOGEN INC | $23,264,000 | +28.4% | 3,381,439 | 0.0% | 0.91% | +18.4% | |
| ZFGN | ZAFGEN INC | $18,303,000 | -10.3% | 3,055,603 | 0.0% | 0.72% | -17.3% | |
| NVLS | NIVALIS THERAPEUTICS INC | $17,169,000 | +10.3% | 3,732,412 | 0.0% | 0.68% | +1.8% | |
| FLUIDIGM CORP DELnote 2.750% 2/0 | $16,658,000 | +8.5% | 27,715,000 | 0.0% | 0.66% | +0.2% | ||
| AKTX | AKARI THERAPEUTICS PLCsponsored adr | $15,523,000 | -3.6% | 1,150,700 | 0.0% | 0.61% | -11.1% | |
| IVTY | INVUITY INC | $12,646,000 | +32.0% | 1,327,009 | 0.0% | 0.50% | +21.8% | |
| CTMX | CYTOMX THERAPEUTICS INC | $9,637,000 | -20.8% | 943,433 | 0.0% | 0.38% | -26.8% | |
| RGNX | REGENXBIO INC | $9,352,000 | -25.9% | 1,169,042 | 0.0% | 0.37% | -31.6% | |
| ALIM | ALIMERA SCIENCES INC | $7,230,000 | -29.7% | 5,878,015 | 0.0% | 0.28% | -35.2% | |
| CASM | CAS MED SYS INC | $5,888,000 | +29.6% | 3,200,000 | 0.0% | 0.23% | +19.7% | |
| LOXO | LOXO ONCOLOGY INC | $5,818,000 | -15.2% | 251,000 | 0.0% | 0.23% | -21.6% | |
| KMPH | KEMPHARM INC | $5,654,000 | -72.5% | 1,420,497 | 0.0% | 0.22% | -74.7% | |
| ARLZ | ARALEZ PHARMACEUTICALS INC | $5,427,000 | -7.0% | 1,644,583 | 0.0% | 0.21% | -14.5% | |
| ADHD | ALCOBRA LTD | $4,804,000 | +18.5% | 1,069,914 | 0.0% | 0.19% | +9.2% | |
| MYOK | MYOKARDIA INC | $4,648,000 | +15.8% | 374,800 | 0.0% | 0.18% | +7.0% | |
| STDY | STEADYMED LTD | $4,404,000 | +32.9% | 1,346,744 | 0.0% | 0.17% | +22.7% | |
| NEOS | NEOS THERAPEUTICS INC | $4,253,000 | -14.0% | 458,332 | 0.0% | 0.17% | -20.9% | |
| PSDV | PSIVIDA CORP | $4,225,000 | +5.6% | 1,492,824 | 0.0% | 0.17% | -2.4% | |
| OXFD | OXFORD IMMUNOTEC GLOBAL PLC | $4,181,000 | -9.2% | 464,541 | 0.0% | 0.16% | -16.3% | |
| VYGR | VOYAGER THERAPEUTICS INC | $2,586,000 | +25.9% | 235,294 | 0.0% | 0.10% | +17.2% | |
| CATB | CATABASIS PHARMACEUTICALS IN | $2,381,000 | -26.6% | 643,580 | 0.0% | 0.09% | -31.9% | |
| ARDX | ARDELYX INC | $2,401,000 | +12.4% | 275,000 | 0.0% | 0.09% | +3.3% | |
| ACUR | ACURA PHARMACEUTICALS INC | $1,897,000 | -34.7% | 1,025,641 | 0.0% | 0.08% | -39.5% | |
| AGRX | AGILE THERAPEUTICS INC | $1,903,000 | +22.5% | 250,000 | 0.0% | 0.08% | +13.6% | |
| ATEC | ALPHATEC HOLDINGS INC | $1,745,000 | +45.9% | 4,982,738 | 0.0% | 0.07% | +35.3% | |
| TRILLIUM THERAPEUTICS INC | $1,547,000 | -2.9% | 172,307 | 0.0% | 0.06% | -10.3% | ||
| CORSICANTO LTDnote 3.500% 1/1 | $1,021,000 | +24.4% | 1,000,000 | 0.0% | 0.04% | +14.3% | ||
| STRM | STREAMLINE HEALTH SOLUTIONS | $796,000 | -14.9% | 662,971 | 0.0% | 0.03% | -22.5% | |
| RENNOVA HEALTH INC*w exp 12/30/202 | $27,000 | -47.1% | 645,161 | 0.0% | 0.00% | -50.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.